Internal Medicine, Gastroenterology · Lancaster, PA
NPI
1447354410
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2112 Harrisburg Pike, Suite 202
Lancaster, PA, 17601
Phone (717) 544-3500
Groups this clinician bills Medicare through
Medicare paid, 2024
$157K
7,112 services
Medicare patients, 2024
341
Average age 73
Drug cost, 2024
$3.8M
775 prescriptions
Company payments, 2025
$66K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John D Betteridge was code J1745 (injection, infliximab, excludes biosimilar, 10 mg), 1,010 times for 14 patients. In total John D Betteridge billed 7,112 services in 52 codes, and Medicare paid $157K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 1,010 | 14 | $23.20 | $23K |
| 99214 Office E&M - Established | Office | 104 | 73 | $83.71 | $8,706 |
| 45385 Colonoscopy - Lesion Removal | Facility | 67 | 67 | $190.45 | $13K |
| 45380 Lower GI Endoscopy - Other | Facility | 52 | 51 | $108.61 | $5,648 |
| 43239 Upper GI Endoscopy | Facility | 40 | 38 | $74.25 | $2,970 |
| 99223 Hospital E&M - Initial | Facility | 36 | 36 | $130.95 | $4,714 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 32 | 32 | $165.38 | $5,292 |
| 99213 Office E&M - Established | Office | 28 | 28 | $58.64 | $1,642 |
| 99232 Hospital E&M - Subsequent | Facility | 26 | 18 | $59.29 | $1,542 |
| 99231 Hospital E&M - Subsequent | Facility | 25 | 20 | $37.24 | $931 |
| 99222 Hospital E&M - Initial | Facility | 18 | 18 | $97.73 | $1,759 |
| 96413 Chemotherapy Administration | Office | 16 | 14 | $88.49 | $1,416 |
| 96415 Chemotherapy Administration | Office | 16 | 14 | $19.16 | $307 |
| 96365 Intravenous Infusion, Hydration | Office | 14 | 11 | $45.88 | $642 |
By year: 2022 $96K for 2,531 services; 2023 $192K for 7,610 services; 2024 $157K for 7,112 services.
Medicare prescription drug claims, 2024
In 2024, the drug John D Betteridge prescribed most often to Medicare patients was Stelara (Ustekinumab), with 71 prescriptions and refills. In total John D Betteridge wrote 775 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 71 | 121 | 13 | $2.2M |
| Omeprazole Generic | 66 | 152 | 28 | $625 |
| Humira(Cf) Pen Adalimumab | 59 | 61 | Under 11 | $585K |
| Esomeprazole Magnesium Generic | 38 | 88 | 18 | $1,858 |
| Mesalamine Er Mesalamine | 35 | 65 | Under 11 | $8,440 |
| Lansoprazole Generic | 25 | 39 | Under 11 | $3,187 |
| Inflectra Infliximab-Dyyb | 25 | 41 | Under 11 | $180K |
| Azathioprine Generic | 24 | 52 | Under 11 | $2,563 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 24 | 30 | Under 11 | $464 |
| Entyvio Vedolizumab | 22 | 41 | Under 11 | $191K |
| Mesalamine Generic | 20 | 49 | Under 11 | $12K |
| Sodium Chloride 0.9 % Sodium Chloride | 19 | 31 | Under 11 | $74.51 |
| Pantoprazole Sodium Generic | 19 | 47 | 11 | $460 |
| Prednisone Generic | 16 | 21 | Under 11 | $139 |
| Sulfasalazine Generic | 15 | 35 | Under 11 | $718 |
Brand drugs: 327 claims; generic drugs: 448 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John D Betteridge $66K ($66K in general payments such as food, travel and fees) from 14 companies. The largest payer was Janssen Biotech, Inc. with $34K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 27 | $34K |
| Abbvie Inc. ABBV | 32 | $18K |
| Pfizer Inc. PFE | 13 | $13K |
| Celltrion USA Inc. 068270.KS | 8 | $165 |
| Novo Nordisk Inc NVO | 5 | $103 |
| Genzyme Corporation SNY | 4 | $101 |
| Lilly USA, LLC LLY | 5 | $97.72 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $97.47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $65.86 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $60.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.